Vera Therapeutics Completes Enrollment For Primary Endpoint In Pivotal Phase 3 ORIGIN 3 Trial Of Atacicept In IgAN
Vera Therapeutics Completes Enrollment For Primary Endpoint In Pivotal Phase 3 ORIGIN 3 Trial Of Atacicept In IgAN
-
On track to announce topline results from ORIGIN 3 trial in Q2 2025
- Expect to present 96-week data from ORIGIN Phase 2b clinical trial of atacicept in IgAN in Q4 2024
- 计划在2025年第二季度公布ORIGIN 3试验的最终结果
- 预计在2024年第四季度展示atacicept在IgAN的ORIGIN Phase 2临床试验的96周数据
BRISBANE, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has completed enrollment ahead of schedule for the primary endpoint in the pivotal Phase 3 ORIGIN 3 trial of atacicept in patients with IgAN. The enrollment of 200 participants in this initial cohort of the trial will provide data for the 36-week UPCR primary efficacy endpoint, supporting the subsequent submission for regulatory approval.
加州布里斯班，2024年9月12日，Vera Therapeutics, Inc.（纳斯达克股票代码：VERA）宣布已提前完成IgAN患者ORIGIN 3关键的III期atacicept试验的初级终点的招募，该试验的初始队列中共有200名参与者，将提供为期36周的UPCR主要疗效终点数据，以支持随后的监管批准递交。